Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5303)	9/14/1998 3:25:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Newsletter Editor McCamant: Biotechs To See Gains September 14, 1998 Dow Jones Newswires NEW YORK -- The biotechnology industry will be a leading sector once the stock market regains some stability, according to Jim McCamant, editor of the Medical Technology Stock Letter. In an interview on CNBC Monday, McCamant said one of the reasons the biotech sector is in good shape is its lack of exposure to overseas economic conditions. In the biotech area, McCamant likes Chiron Corp. (CHIR), Agouron Pharmaceuticals Inc. (AGPH), Isis Pharmaceuticals Inc. (ISIP), ICOS Corp. (ICOS) and AXYS Pharmaceuticals Inc. (AXPH). -By Victor Ozols; 201-938-5394